Medexus Pharmaceuticals Inc (MDP.TO) stock: key figures, P/E, revenue and dividend
Health Care · Pharmaceuticals · Canada · ISIN CA58410Q2036
Medexus Pharmaceuticals Inc financials
| Fiscal year | 2025 | 2026 |
|---|---|---|
| Revenue | 108.33 m USD | 99.33 m USD |
| Gross profit | 56.58 m USD | 54.41 m USD |
| Operating income | 8.22 m USD | 5.84 m USD |
| EBIT | 9.64 m USD | 2.93 m USD |
| Net income | 2.25 m USD | -2.39 m USD |
| Diluted EPS – continuing operations | 0.08 USD | -0.07 USD |
Full history since 2012, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Medexus Pharmaceuticals Inc
Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. Its primary products include IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis, psoriasis, and juvenile idiopathic arthritis; Rupall, a prescription allergy medication; and GRAFAPEX, an injection to treat allogeneic hematopoietic stem cell transplantation in adult and pediatric patients, acute myeloid leukemia (AML), and myelodysplastic syndrome. The company's products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, a ciprofloxacin and flucinolone acetonide; and intraarticular, a triamcinolone hexacetonide injectable suspension. In addition, it offers over the counter products comprising Nyda, a topical treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; and Calcia Calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. was founded in 2000 and is based in Toronto, Canada.
More stocks
- KNR System Inc. (199430.KQ)
- Sungshin Cemen (004980.KS)
- Potens Semiconductor Corp. (7712.TWO)
- Adriano Care SOCIMI SAU (YADR.MC)
- BioPlus Co. Ltd. (099430.KQ)
- Bookook Securities Co Ltd (001275.KS)
- TerrAscend Corp. (TSNDF)
- Medigen Biotechnology (3176.TWO)
- SHL Consolidated Bhd (6017.KL)
- Hsin Kao Gas Co Ltd (9931.TW)
- Inclusio Sca (INCLU.BR)
- Tander Inversiones SOCIMI SA (YTAN.MC)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.